Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Priority to CU20090039ApriorityCriticalpatent/CU20090039A7/en
Publication of CU20090039A7publicationCriticalpatent/CU20090039A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Pyridine Compounds
(AREA)
Abstract
La presente invención se refiere a 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-N-metilpiridina-2-carboxamida monohidrato, a procedimientos para su preparación, a composiciones farmacéuticas que lo comprenden y a su uso en el combate de trastornos.The present invention relates to 4- [4 - ({[4-chloro-3- (trifluoromethyl) phenyl] carbamoyl} amino) -3-fluorophenoxy] -N-methylpyridine-2-carboxamide monohydrate, to processes for its preparation, to pharmaceutical compositions that comprise it and its use in the combat of disorders.
A method for inhibiting or reducing thalamic damage in a subject affected by multiple sclerosis comprising the administration of laquinimod; pharmaceutical composition
Composition containing s- [2 - ([[1- (2-ethylbutyl) -cyclohexyl] -carbonyl] amino) phenyl] 2-methylpropanothioate] and croscarmellose sodium; Preparation process; tablet that contains it; kit and use in the treatment and prevention of cardiovascular disorders.